2025 marked a decisive breakthrough year for Bitget, the world’s largest Universal Exchange (UEX). All details.2025 marked a decisive breakthrough year for Bitget, the world’s largest Universal Exchange (UEX). All details.

Bitget’s Breakout Year: How the World’s Largest UEX Redefined Finance, Transparency and AI-Powered Trading in 2025

2025 marked a decisive breakthrough year for Bitget, the world’s largest Universal Exchange (UEX). Through product innovation, institutional expansion, AI adoption and industry-leading transparency, Bitget delivered one of its strongest twelve-month performances to date, cementing its position at the heart of the global digital asset economy.

The company’s founding ambition was to bring together CeFi, DeFi, RWAs, tokenized stocks and AI-driven trading under one roof. That vision has now taken shape as a functioning ecosystem used by millions of traders and investors worldwide.

Bitget’s most notable achievement in 2025 was the rapid maturation of its Universal Exchange model. While traditional exchanges faced difficulties keeping pace with growing fragmentation across centralized platforms, decentralized liquidity and tokenized traditional assets, Bitget’s UEX model demonstrated what the future of digital finance could look like: Open, interoperable, intelligent and unified.

Bitget Onchain emerged as one of the most influential components of this architecture, unlocking seamless access to decentralized assets directly within a CEX-style interface.

In 2025, daily Onchain trading volumes regularly exceeded $113 million, with users able to route trades across Ethereum, Solana, BNB Chain and Base without switching wallets or navigating blockchain complexities.

This hybrid model — pairing deep CeFi liquidity with the breadth of DeFi — became one of Bitget’s strongest differentiators.

Expanding beyond crypto markets, Bitget also saw major growth in tokenized stocks and real-world assets. Throughout the year, tokenized stock futures experienced intense demand, with overall trading volume surpassing $5 billion, driven by renewed interest in U.S. tech earnings.

The products gave users round-the-clock-access to equities, such as NVDA and TSLA, in contrast to the limited hours offered by traditional brokers. Lower fees and the ability to move between digital assets and tokenized equities within a single balance sheet became key advantages of Bitget’s Universal Exchange model.

If 2025 was the year UEX took shape, it was also the year the company’s AI layer, GetAgent, drew widespread attention in crypto trading circles.

GetAgent moved far beyond traditional chatbot functions, offering real-time analysis, portfolio-specific insights, market depth evaluation, personalized daily reports and, crucially, the ability to execute trades directly from chat.

Unlike general AI platforms, like ChatGPT, which are limited to explanations, GetAgent became one of the first industry assistants able to generate entry and exit levels, identify risk-adjusted strategies and execute trades with a single tap.

It combined market data, technical signals, news flow, sentiment and user portfolio context to deliver tailored guidance for both new and advanced traders. Throughout the year, user engagement surged across more than 90 countries, demonstrating strong demand for AI-powered decision frameworks in volatile markets.

Bitget reinforced its institutional position in 2025  through enhanced liquidity partnerships and upgraded market infrastructure. A strengthened relationship with partners, such as Ampersand, provided institutional-grade liquidity across both centralized and decentralized venues — an essential capability for the UEX model, which serves retail traders, market makers and professional desks simultaneously.

Deeper price depth and stronger execution quality helped Bitget present itself as a reliable global venue for institutional flows while continuing to offer the accessibility expected by retail users.

Yet no achievement in 2025 was more consistent — or more important to Bitget’s philosophy — than its transparency record. Throughout the year, Bitget published monthly proof-of-reserves reports, providing evidence of solvency and full over-collateralization during periods of heightened market volatility.

The July, Q3 and October transparency reports all revealed exceptional coverage ratios, with Bitcoin reserves surpassing 300%, Ethereum reserves above 200% and both USDT and USDC fully overcollateralized.

These reports were backed by a continuously updated Merkle-tree verification system, public wallet attestations and a self-check tool that allowed users to confirm inclusion without compromising privacy.

When combined with Bitget’s standing protection fund and transparent PoR portal, the exchange delivered one of the strongest and most verifiable trust frameworks among major global platforms.

These developments reflect a year in which Bitget evolved far beyond the role of an exchange. In 2025, Bitget became a multi-asset, AI-powered, institutionally integrated, transparently backed financial ecosystem, one that redefines what users can expect from a modern trading venue.

The Universal Exchange is no longer a conceptual blueprint but a fully operational model that connects centralized markets, decentralized liquidity, tokenized TradFi assets and intelligent trading capabilities within a single system.

Bitget’s achievements place it at the forefront of a shift towards tokenized markets, AI-assisted decision-making and deeper interoperability between CeFi and DeFi. 2025 was a year of innovation not only in technology but also in trust, accessibility and user empowerment.

Bitget didn’t simply expand in 2025 but set out a blueprint for what the next generation of global exchanges must become.

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26